GO:0045639 positive regulation of myeloid cell differentiation: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045639 describes any process that activates or increases the frequency, rate or extent of myeloid cell differentiation, the process by which hematopoietic progenitors become granulocytes, monocytes, macrophages, dendritic cells and osteoclasts.
• Myeloid differentiation is driven by lineage-restricted transcription factors and cytokine signaling, and is tightly coupled to cell-cycle exit and chromatin remodeling.
• Positive regulators include cytokines such as M-CSF and RANKL, transcription factors such as PU.1 and C/EBPalpha, and epigenetic modifiers such as TET2.
• Dysregulation of positive regulation of myeloid cell differentiation contributes to myeloid leukemias, myelodysplastic syndromes, osteoporosis and inflammatory disease.
• Experimental models for studying this process include THP-1 and HL-60 cell lines, primary bone marrow cultures, and CRISPR-engineered knockout or knock-in cells.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of candidate regulators of myeloid differentiation.
Description
Myeloid cell differentiation is the developmental process through which multipotent hematopoietic progenitors give rise to mature myeloid lineages, including granulocytes, monocytes, macrophages, dendritic cells and osteoclasts. The Gene Ontology term GO:0045639, positive regulation of myeloid cell differentiation, captures any process that activates or increases the frequency, rate or extent of this differentiation program. Because myeloid cells are central to innate immunity, inflammation and bone homeostasis, understanding the positive regulators of their differentiation is a major goal in hematology and immunology. Positive regulation of myeloid cell differentiation is not a single molecular event but an integrated outcome of cytokine signaling, lineage-restricted transcription factor networks, epigenetic remodeling and cell-cycle control. Cytokines such as macrophage colony-stimulating factor and RANKL provide external instructive signals, while transcription factors such as PU.1 and C/EBPalpha enforce myeloid gene expression programs. Epigenetic regulators, including TET2, modulate the chromatin landscape that permits or blocks differentiation. Experimental systems such as PMA-treated THP-1 cells have been optimized to model macrophage differentiation in vitro, providing a tractable platform for mechanistic studies. Disruption of these positive regulatory circuits is linked to myeloid malignancies, bone loss and aberrant inflammatory responses, making this GO term directly relevant to human disease.
positive regulation of myeloid cell differentiation At A Glance
| GO ID | GO:0045639 |
|---|---|
| GO term | positive regulation of myeloid cell differentiation |
| Ontology | biological_process |
| Synonym | activation of myeloid cell differentiation; stimulation of myeloid cell differentiation; up regulation of myeloid cell differentiation; up-regulation of myeloid cell differentiation; upregulation of myeloid cell differentiation |
| Major function | Increases the frequency, rate or extent of myeloid cell differentiation |
| Biological context | Hematopoiesis, innate immunity, inflammation and bone remodeling |
| Key cell types | Granulocytes, monocytes, macrophages, dendritic cells, osteoclasts |
| Representative regulators | Cytokines (M-CSF, RANKL), transcription factors (PU.1, C/EBPalpha), epigenetic modifiers (TET2) |
| Disease relevance | Myeloid leukemia, myelodysplastic syndromes, osteoporosis, inflammatory disease |
What Is GO:0045639?
GO:0045639, positive regulation of myeloid cell differentiation, is defined as any process that activates or increases the frequency, rate or extent of myeloid cell differentiation. In practical terms, it refers to the collection of molecular and cellular events that push a progenitor cell toward a mature myeloid fate, rather than simply permitting differentiation to occur. This includes cytokine-driven signaling, activation of lineage-determining transcription factors, chromatin changes that open myeloid gene loci, and the metabolic and cell-cycle adjustments that accompany differentiation.
Why Is positive regulation of myeloid cell differentiation Important in Cell Biology?
Positive regulation of myeloid cell differentiation is important because it determines the size and composition of the myeloid compartment, which is essential for innate immune defense, tissue homeostasis and bone remodeling. When positive regulators are lost or hyperactivated, the balance between progenitor self-renewal and differentiation shifts, contributing to myeloid malignancies, bone loss and chronic inflammation. Understanding these regulators therefore informs both basic hematopoiesis and therapeutic strategies targeting myeloid-driven disease.
• Controls the production of granulocytes, monocytes, macrophages and dendritic cells required for innate immunity.
• Regulates osteoclast differentiation, linking myeloid biology to bone homeostasis and osteoporosis.
• Provides a mechanistic framework for understanding myeloid leukemia and myelodysplastic syndromes.
• Influences inflammatory and immunosuppressive cell populations, including myeloid-derived suppressor cells.
• Is coupled to cell-cycle exit and chromatin remodeling, making it a model for cell fate decisions.
• Can be modeled in vitro using THP-1 and HL-60 cell lines, enabling reproducible mechanistic studies.
• Represents a target for therapeutic modulation in bone disease and cancer.
• Requires integration of cytokine signaling, transcription factor networks and epigenetic regulation.
What Happens During positive regulation of myeloid cell differentiation?
Cytokine and growth factor signaling
In simple terms: External signals tell the progenitor cell to start becoming a myeloid cell.
Positive regulation of myeloid cell differentiation begins with extracellular cues, notably cytokines such as macrophage colony-stimulating factor and RANKL, which bind surface receptors on hematopoietic progenitors and initiate intracellular signaling cascades. These signals activate transcription factors that commit the cell to a myeloid fate and promote survival and proliferation of differentiating cells. Stromal cells in the bone marrow also provide supportive signals that regulate both lymphoid and myeloid differentiation.
Transcription factor network activation
In simple terms: Master switches inside the cell turn on the myeloid gene program.
Lineage-determining transcription factors such as PU.1 and C/EBPalpha are activated downstream of cytokine signaling and cooperate to induce myeloid-specific genes while repressing alternative lineage programs. These factors bind enhancers and promoters of myeloid genes, initiating the transcriptional changes required for differentiation. The balance and timing of these transcription factors are critical for proper myeloid cell development.
Chromatin remodeling and epigenetic changes
In simple terms: The cell's DNA packaging is loosened so myeloid genes can be read.
Chromatin-state barriers enforce irreversible cell fate decisions, and positive regulation of myeloid differentiation requires remodeling of the chromatin landscape to make myeloid gene loci accessible. Epigenetic modifiers such as TET2 modulate DNA methylation and chromatin structure, influencing the differentiation program. Disruption of these epigenetic regulators can block or skew differentiation, as seen in TET2-deficient models.
Cell-cycle exit and maturation
In simple terms: The cell stops dividing and matures into a functional myeloid cell.
As differentiation proceeds, progenitors exit the cell cycle and acquire lineage-specific functions such as phagocytosis or bone resorption. This maturation step is coupled to changes in metabolism and gene expression that are part of the positive regulatory program. In osteoclast differentiation, for example, cells undergo cell-cell fusion to form multinucleated bone-resorbing cells, a process regulated by RANKL and downstream factors.
Integration with inflammatory and immune signals
In simple terms: Inflammation can push myeloid cells to differentiate faster or differently.
Inflammatory mediators and tumor-derived factors can modulate positive regulation of myeloid cell differentiation, for example by expanding myeloid-derived suppressor cells through chemokine pathways such as CCL20-CXCL2-CXCR2. This integration allows the myeloid compartment to adapt to infection, tissue damage or cancer. Such context-dependent regulation is a key reason the process is studied in disease models.
Key Genes Involved in GO:0045639 positive regulation of myeloid cell differentiation
The following genes and proteins are representative regulators and markers of positive regulation of myeloid cell differentiation, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPI1 (PU.1) | Master transcription factor for myeloid lineage commitment | Knockout blocks myeloid differentiation; key target for differentiation studies |
| CEBPA | Transcription factor promoting granulocyte and monocyte differentiation | Mutations linked to leukemia; models of differentiation arrest |
| CSF1R | Receptor for M-CSF, drives monocyte/macrophage differentiation | Target for knockout and inhibitor studies |
| TNFSF11 (RANKL) | Cytokine essential for osteoclast differentiation | Knockout causes osteopetrosis; key osteoporosis model |
| TNFRSF11A (RANK) | Receptor for RANKL on osteoclast precursors | Knockout blocks osteoclastogenesis; used in bone studies |
| TET2 | Epigenetic modifier regulating DNA demethylation | Knockout alters osteoclastogenesis and differentiation |
| STOM (stomatin) | Lipid raft protein involved in osteoclast function | Target for osteoporosis intervention in preclinical models |
| CCL20 | Chemokine modulating myeloid-derived suppressor cells | Linked to breast cancer stemness via CXCL2-CXCR2 |
| CXCL2 | Chemokine acting through CXCR2 | Mediates myeloid cell recruitment and function in tumors |
| CXCR2 | Receptor for CXCL2 | Involved in myeloid cell trafficking and cancer progression |
| NFATC1 | Transcription factor downstream of RANKL in osteoclasts | Knockout blocks osteoclast differentiation |
| MITF | Transcription factor cooperating with PU.1 in osteoclasts | Regulates osteoclast gene expression |
| CTSK (cathepsin K) | Protease secreted by mature osteoclasts | Marker of osteoclast maturation |
| ACP5 (TRAP) | Enzyme marker of osteoclasts | Used to assess osteoclast differentiation |
| ITGB3 (integrin beta3) | Adhesion receptor in osteoclasts | Marker of mature osteoclasts |
| CD14 | Monocyte/macrophage surface marker | Used to monitor THP-1 differentiation |
| CD11b (ITGAM) | Myeloid surface marker | Readout of myeloid differentiation |
| LYZ (lysozyme) | Myeloid enzyme marker | Indicator of macrophage differentiation |
How Is positive regulation of myeloid cell differentiation Regulated?
Positive regulation of myeloid cell differentiation is controlled at multiple levels. Cytokine signaling through receptors such as CSF1R and TNFRSF11A initiates differentiation programs. Transcription factors including PU.1, C/EBPalpha, NFATC1 and MITF form feed-forward loops that reinforce the myeloid fate. Epigenetic regulators such as TET2 modulate chromatin accessibility and DNA methylation, and their loss alters differentiation outcomes. Chromatin-state barriers can enforce irreversible fate decisions, meaning that once cells commit to a myeloid program, they may not readily revert. Inflammatory and tumor-derived signals, including chemokines such as CCL20 and CXCL2, can further modulate the rate and direction of differentiation in disease contexts.
positive regulation of myeloid cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TET2 | Osteoclastogenesis and bone loss | Tet2 knockout mice, OVX-induced bone loss model |
| STOM | Osteoporosis | Stom knockout or overexpression in osteoclast precursors |
| CCL20 | Breast cancer and myeloid-derived suppressor cells | Tumor xenografts with CCL20 knockdown |
| TNFSF11 (RANKL) | Osteoporosis and osteopetrosis | Rankl knockout mice, osteoclast differentiation cultures |
| SPI1 (PU.1) | Myeloid leukemia | PU.1 knockdown or knockout in hematopoietic cells |
Myeloid leukemia and myelodysplastic syndromes
Disruption of positive regulation of myeloid cell differentiation can lead to differentiation arrest and accumulation of immature myeloid cells, hallmark features of acute myeloid leukemia and myelodysplastic syndromes. Mutations or epigenetic changes affecting transcription factors and chromatin regulators contribute to these diseases. Studying how positive regulators are lost or bypassed provides insight into leukemogenesis.
Osteoporosis and bone loss
Osteoclasts are myeloid-derived cells, and their differentiation is positively regulated by RANKL and downstream factors. Excessive osteoclast differentiation contributes to osteoporosis and inflammatory bone loss, while impaired differentiation causes osteopetrosis. Targeting regulators such as TET2 or stomatin has been explored to ameliorate bone loss in preclinical models.
Cancer and immunosuppression
Tumors can modulate myeloid differentiation to expand immunosuppressive populations such as myeloid-derived suppressor cells. Chemokine pathways including CCL20-CXCL2-CXCR2 promote breast cancer stemness through effects on myeloid cells. Understanding positive regulation of myeloid differentiation in the tumor microenvironment may inform immunotherapy strategies.
From positive regulation of myeloid cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene block myeloid differentiation? | CRISPR knockout in THP-1 or HL-60 cells |
| Does a specific point mutation alter differentiation capacity? | CRISPR point-mutation knock-in in primary progenitors |
| Does overexpression of a regulator accelerate differentiation? | Lentiviral overexpression in myeloid cell lines |
| How does a tagged protein behave during differentiation? | Endogenous tagged knock-in in hematopoietic stem cells |
| Which genes are required for osteoclast differentiation? | CRISPR knockout in bone marrow-derived macrophages |
| How do epigenetic regulators affect differentiation? | TET2 knockout or catalytic-dead knock-in models |
How to Study the positive regulation of myeloid cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface markers of myeloid differentiation | Quantifying CD14+ or CD11b+ cells |
| RNA-seq | Transcriptional changes during differentiation | Identifying positive regulators and pathways |
| ATAC-seq | Chromatin accessibility | Mapping epigenetic barriers to differentiation |
| CRISPR knockout | Loss-of-function effects on differentiation | Testing candidate positive regulators |
| CRISPR knock-in | Effects of specific mutations or tags | Modeling disease variants or tracking proteins |
| TRAP staining | Osteoclast differentiation | Bone marrow-derived osteoclast cultures |
| Micro-CT | Bone mass and structure | Osteoporosis models |
| Western blot | Protein expression and signaling | Validating pathway activation |
Cell culture and differentiation assays
In vitro models such as PMA-treated THP-1 cells and cytokine-driven primary bone marrow cultures allow controlled induction of myeloid differentiation. Differentiation is monitored by surface markers such as CD14 and CD11b, and by morphological changes. These assays provide a first-pass readout for positive regulators.
Transcriptomic and epigenomic profiling
RNA-seq and ATAC-seq can map gene expression and chromatin accessibility changes during differentiation, revealing transcription factor networks and epigenetic remodeling events. Such profiling helps identify positive regulators and their downstream targets. Integration with chromatin-state maps can reveal barriers to fate commitment.
Functional perturbation with CRISPR
CRISPR knockout, point-mutation, knock-in and overexpression enable causal testing of candidate regulators in myeloid differentiation models. Pooled CRISPR screens can identify genes whose loss increases or decreases differentiation. These approaches are central to validating positive regulators.
In vivo bone and tumor models
Ovariectomy-induced bone loss and tumor xenograft models allow assessment of myeloid differentiation regulators in vivo. Histology, micro-CT and flow cytometry are used to quantify osteoclasts and myeloid populations. These models bridge in vitro findings to disease relevance.
How CRISPR Can Be Used to Study GO:0045639 positive regulation of myeloid cell differentiation
Knockout
CRISPR knockout of candidate genes in myeloid cell lines or primary progenitors can determine whether a gene is required for positive regulation of myeloid cell differentiation. For example, Tet2 knockout alters osteoclastogenesis in bone loss models. Knockout screens can systematically identify regulators.
Point Mutation
CRISPR point-mutation knock-in allows modeling of specific disease-associated variants or catalytic-dead alleles in regulators of myeloid differentiation. This approach distinguishes loss-of-function from gain-of-function mechanisms. It is particularly useful for epigenetic enzymes such as TET2.
Knock-in
Knock-in of tags or reporters enables tracking of endogenous proteins during differentiation and can reveal dynamic expression or localization. Knock-in of lineage markers can also facilitate sorting of differentiating cells. This approach supports precise mechanistic studies.
Overexpression
CRISPR activation or lentiviral overexpression can test whether increasing a regulator enhances myeloid differentiation. Overexpression of chemokines such as CCL20 modulates myeloid cell populations in tumor models. This complements loss-of-function studies.
How EDITGENE Supports positive regulation of myeloid cell differentiation Research
Researchers studying positive regulation of myeloid cell differentiation-related genes often need to determine whether a candidate gene is causally involved in differentiation, and whether specific mutations alter that function. EDITGENE provides CRISPR-based cell model services that enable such causal testing in relevant myeloid backgrounds.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of myeloid cell differentiation research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CSF3 Knockout HEK293 Cell Line | EDJ-KQ457 | Human | 1440 | Details Get a Quote |
| FES Knockout HEK293 Cell Line | EDJ-KQ4585 | Human | 2242 | Details Get a Quote |
| HOXA5 Knockout HEK293 Cell Line | EDJ-KQ4901 | Human | 3202 | Details Get a Quote |
| FES Knockout A-549 Cell Line | EDJ-KQ27241 | Human | 2242 | Details Get a Quote |
| FES Knockout HCT 116 Cell Line | EDJ-KQ27242 | Human | 2242 | Details Get a Quote |
| HOXA5 Knockout A-549 Cell Line | EDJ-KQ27721 | Human | 3202 | Details Get a Quote |
| HOXA5 Knockout HCT 116 Cell Line | EDJ-KQ27722 | Human | 3202 | Details Get a Quote |
| HOXA5 Knockout HeLa Cell Line | EDJ-KQ27723 | Human | 3202 | Details Get a Quote |
| Csf3 Knockout RAW 264.7 Cell Line | EDJ-KZ17 | Mouse | 12985 | Details Get a Quote |
| CSF3 Knockout HeLa Cell Line | EDJ-KQ53003 | Human | 1440 | Details Get a Quote |
| FES Knockout HeLa Cell Line | EDJ-KQ53217 | Human | 2242 | Details Get a Quote |
| CSF3 Knockout A-549 Cell Line | EDJ-KQ61469 | Human | 1440 | Details Get a Quote |
| CSF3 Knockout HCT 116 Cell Line | EDJ-KQ69966 | Human | 1440 | Details Get a Quote |
Displaying Records 1 To 13 Of 13 Records
Frequently Asked Questions About positive regulation of myeloid cell differentiation
What is GO:0045639 positive regulation of myeloid cell differentiation?
It is a Gene Ontology biological process term describing any process that activates or increases the frequency, rate or extent of myeloid cell differentiation.
What genes are involved in positive regulation of myeloid cell differentiation?
Key genes include SPI1 (PU.1), CEBPA, CSF1R, TNFSF11 (RANKL), TNFRSF11A (RANK), TET2, NFATC1 and MITF, among others.
How is myeloid cell differentiation positively regulated?
It is positively regulated by cytokine signaling, lineage-determining transcription factors, epigenetic remodeling and cell-cycle exit.
What cell types arise from myeloid cell differentiation?
Myeloid differentiation gives rise to granulocytes, monocytes, macrophages, dendritic cells and osteoclasts.
How can I study positive regulation of myeloid cell differentiation in the lab?
Common approaches include THP-1 differentiation assays, flow cytometry, RNA-seq, ATAC-seq and CRISPR perturbation.
What diseases are linked to dysregulated myeloid differentiation?
Myeloid leukemia, myelodysplastic syndromes, osteoporosis and cancer-associated immunosuppression are linked to dysregulated myeloid differentiation.
What is the role of TET2 in myeloid differentiation?
TET2 is an epigenetic modifier that regulates osteoclastogenesis and differentiation, and its loss alters these processes in bone loss models.
Can CRISPR be used to study myeloid differentiation?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models are widely used to test regulators of myeloid differentiation.
What is the difference between myeloid cell differentiation and positive regulation of myeloid cell differentiation?
Myeloid cell differentiation is the process itself, while positive regulation refers to processes that increase its frequency, rate or extent.
Which experimental models are suitable for studying osteoclast differentiation?
Bone marrow-derived macrophage cultures, RANKL stimulation and ovariectomy-induced bone loss models are commonly used.
Conclusion
GO:0045639 positive regulation of myeloid cell differentiation defines the processes that drive progenitors toward mature myeloid fates, integrating cytokine signals, transcription factor networks and epigenetic remodeling. This process is central to immunity, bone homeostasis and cancer biology, and its dysregulation underlies several human diseases. CRISPR-based models and multi-omics methods provide powerful tools to dissect these regulatory mechanisms and to identify therapeutic targets.
References
- 1. Liu T et al.. 2023. Optimization of differentiation and transcriptomic profile of THP-1 cells into macrophage by PMA.. PLoS One 18(7):e0286056 PMID: 37459313
- 2. Tao H et al.. 2025. Targeting lipid raft-related stomatin to ameliorate osteoporosis in preclinical models.. Nat Commun 16(1):5495 PMID: 40595453
- 3. Yang C et al.. 2022. TET2 regulates osteoclastogenesis by modulating autophagy in OVX-induced bone loss.. Autophagy 18(12):2817-2829 PMID: 35255774
- 4. Quesenberry PJ et al.. 1987. Stromal cell regulation of lymphoid and myeloid differentiation.. Blood Cells 13(1-2):137-46 PMID: 3311214
- 5. Roodman GD. 2006. Regulation of osteoclast differentiation.. Ann N Y Acad Sci 1068:100-9 PMID: 16831910
- 6. Zhang R et al.. 2023. PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway.. Signal Transduct Target Ther 8(1):97 PMID: 36859354
- 7. Blanco MA et al.. 2021. Chromatin-state barriers enforce an irreversible mammalian cell fate decision.. Cell Rep 37(6):109967 PMID: 34758323
- 8. Miyamoto T. 2011. Regulators of osteoclast differentiation and cell-cell fusion.. Keio J Med 60(4):101-5 PMID: 22200633
